Señales en vivo de EVAX | Maximiza tus Ganancias con Getagraph.com

COMPRAR 106055 min ago

@ $4.00

Emitido: 13 feb 2024 @ 15:29

Retorno: 4.50%

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections...

Stats
Volumen de hoy	24 736.00
Volumen promedio	95 606.00
Capitalización de mercado	21.80M
EPS	$0 ( 2023-12-18 )
Próxima fecha de ganancias	( $-0.550 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.520
ATR14	$0.0690 (1.72%)

Evaxion Biotech A/S Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Evaxion Biotech A/S Finanzas

Annual	2023
Ingresos:	$73 112.00
Beneficio Bruto:	$73 112.00 (100.00 %)
EPS:	$-8.11

FY	2023
Ingresos:	$73 112.00
Beneficio Bruto:	$73 112.00 (100.00 %)
EPS:	$-8.11

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-571 319 (0.00 %)
EPS:	$-9.80

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.514

Financial Reports:

No articles found.

Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.